Lower respiratory tract infections: Acute bacterial bronchitis due to Streptococcus pneumoniae, Haemophilus influenza or Moraxella carterrhalis; Community-acquired pneumonia due to Streptococcus pneumoniae or Haemophilus influenza in patients suitable for outpatient oral treatment; Community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. In clinical studies efficacy has been demonstrated again Chlamydia, Haemophilus influenza, Legionella pneumophilia, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus and Streptococcus pneumoniae. Upper respiratory infections: Acute sinusitis due to Streptococcus pneumonia or Haemophilus influenza; Acute Streptoccocal pharyngitis due to Streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. Acute otitis media. Uncomplicated skin and skin structure infections: Uncomplicated infections due to Staphylococcus aureus, Streptococcus pyogenes or Streptococcus agalactiae; Abscesses usually require surgical drainage. Sexually transmitted diseases: Uncomplicated urethritis and cervcitis due to Chlamydia trachomatis or non – multiresistant Neisseria gonorrhea; Pelvic inflammatory disease caused by susceptible organisms, (Chlamydia trachomatis, Neisseria gonorrhea, Mycoplasma hominis) in patients who require initial intravenous therapy. Chlamydia trachomatis conjunctivitis and trachoma. Prevention due to Mycobacterium avium-intracellulare Complex (MAC) Disease, when used as the sole agent or in combination with rifabutin at its approved dose, in adults with HIV infection and CD4 cell count less than or equal to 75 cells/µL.